Sort
48,018 grants matching “immunotherapy”
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia
$474,108Jay K Kolls · Tulane University Of Louisiana · R01 · FY2024 · AI
AHR-mediated immunosuppression in glioblastoma
$474,075Francisco J. Quintana · Brigham And Women'S Hospital · R01 · FY2022 · ES
DEVELOPMENTAL FUNDS (Core-002)
$474,044Beverly Shriver Mitchell · Stanford University · P30 · FY2020 · CA
Vascular image-guided optimization of response (VIGOR) to therapy in kidney cancer
$474,043Ralph P Mason · Ut Southwestern Medical Center · R01 · FY2021 · CA
Immunomodulation targeting abnormal conformation and the influence of apoE
$474,020Fernando Goni · New York University School Of Medicine · P01 · FY2023 · AG
Immunomodulation targeting abnormal conformation and the influence of apoE
$474,020Fernando Goni · New York University School Of Medicine · P01 · FY2021 · AG
Project 2: Combination immunotherapy approaches to overcome therapeutic resistance in HER2-positive breast cancer
$473,960Ian E Krop · Dana-Farber Cancer Inst · P50 · FY2020 · CA
Immunochemotherapy in Visceral Leishmaniasis
$473,959Henry W. Murray · Weill Medical Coll Of Cornell Univ · R56 · FY2009 · AI
Intrapleural immunotherapeutic nanoparticles for MPE treatment
$473,950Dawen Zhao · Wake Forest University Health Sciences · R01 · FY2021 · CA
Nanoparticles to Track T Cell Immunotherapy Using Magnetic Particle Imaging
$473,925Carlos M Rinaldi-Ramos · University Of Florida · R01 · FY2025 · EB
Determinants of immunotherapy response in NASH-Hepatocellular carcinoma
$473,881Josep M Llovet · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA
Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer
$473,860Dihua Yu · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Metabolic and molecular regulation of myeloid cell functions in brain cancer
$473,753Filippo Veglia · Wistar Institute · R01 · FY2025 · NS
Bacterial Quorum Sensing as Target for Anti-Infective Immunotherapy
$473,750Gunnar Joerg Floris Kaufmann · Scripps Research Institute, The · R01 · FY2009 · AI
JAML: A New Costimulatory Molecule for Gamma Delta T Cells
$473,750Wendy L Havran · Scripps Research Institute, The · R01 · FY2012 · AI
Discovery of potent human antibodies for prevention of (recurrent) HCV infection
$473,750Mansun Law · Scripps Research Institute, The · R01 · FY2009 · AI
JAML: A New Costimulatory Molecule for Gamma Delta T Cells
$473,750Wendy L Havran · Scripps Research Institute, The · R01 · FY2015 · AI
Discovery of potent human antibodies for prevention of (recurrent) HCV infection
$473,750Mansun Law · Scripps Research Institute, The · R01 · FY2008 · AI
Targeting UHRF1 in combinational immunotherapy
$473,749Xiao-Fan Wang · Duke University · R01 · FY2019 · CA
A modular cell therapy platform for controlling immunological tolerance
$473,726Nathan Edward Reticker-Flynn · Stanford University · DP2 · FY2023 · AI
PD-1/PD-L1 modulation in cancer therapy
$473,681Drew M. Pardoll · Johns Hopkins University · R01 · FY2019 · CA
Expanding the tumor antigen landscape and maintaining APCs in a T cell-activating state to restore tumor immunity
$473,680Eduardo Davila · University Of Colorado Denver · R01 · FY2025 · CA
A Wholly Protein-based Self-assembly Nanoplatform for TNBC-specific Combination Therapy
$473,654Rihe Liu · Univ Of North Carolina Chapel Hill · R01 · FY2023 · EB
A Wholly Protein-based Self-assembly Nanoplatform for TNBC-specific Combination Therapy
$473,654Rihe Liu · Univ Of North Carolina Chapel Hill · R01 · FY2025 · EB
A Wholly Protein-based Self-assembly Nanoplatform for TNBC-specific Combination Therapy
$473,654Rihe Liu · Univ Of North Carolina Chapel Hill · R01 · FY2022 · EB